Cancer Nanomedicine: Emerging Strategies and Therapeutic Potentials
Abstract
:1. Introduction
2. Nanoparticle-Mediated Drug Delivery
2.1. Mechanisms of Nanoparticle-Mediated Drug Delivery
2.1.1. Passive Targeting
2.1.2. Active Targeting
2.1.3. Drug Release
2.2. Benefits of NP-Mediated Drug Delivery
3. The Promising Role of Nanomedicine in Tumor Therapies
3.1. Surgery
3.2. Chemotherapy
3.3. Immunotherapy
3.4. Radiotherapy
3.5. Photodynamic and Photothermal Therapy
3.6. Gene Therapy
3.7. Diagnosis and Imaging
4. Prospective View
4.1. Prospects and Challenges of Nanomedicine in Tumor Therapeutics
4.2. Directions for Novel Nanomedicine Development in Tumor Treatment
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Siegel, R.L.; Miller, K.D.; Jemal, A. Cancer statistics, 2018. CA Cancer J. Clin. 2018, 68, 7–30. [Google Scholar] [CrossRef]
- Cho, K.; Wang, X.; Nie, S.; Chen, Z.; Shin, D.M. Therapeutic nanoparticles for drug delivery in cancer. Clin. Cancer Res. 2008, 14, 1310–1316. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Rugbjerg, K.; Mellemkjær, L.; Boice, J.D.; Køber, L.; Ewertz, M.; Olsen, J.H. Cardiovascular disease in survivors of adolescent and young adult cancer: A Danish cohort study, 1943–2009. JNCI J. Natl. Cancer Inst. 2014, 106, dju110. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Hile, E.S.; Fitzgerald, G.K.; Studenski, S.A. Persistent mobility disability after neurotoxic chemotherapy. Phys. Ther. 2010, 90, 1649–1657. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Pakunlu, R.I.; Wang, Y.; Saad, M.; Khandare, J.J.; Starovoytov, V.; Minko, T. In vitro and in vivo intracellular liposomal delivery of antisense oligonucleotides and anti-cancer drug. J. Control. Release 2006, 114, 153–162. [Google Scholar] [CrossRef] [PubMed]
- Leonard, G.D.; Fojo, T.; Bates, S.E. The role of ABC transporters in clinical practice. Oncologist 2003, 8, 411–424. [Google Scholar] [CrossRef]
- Moses, M.A.; Brem, H.; Langer, R. Advancing the field of drug delivery: Taking aim at cancer. Cancer Cell 2003, 4, 337–341. [Google Scholar] [CrossRef] [Green Version]
- Alexis, F.; Rhee, J.-W.; Richie, J.P.; Radovic-Moreno, A.F.; Langer, R.; Farokhzad, O.C. New frontiers in nanotechnology for cancer treatment. Urol. Oncol. 2008, 26, 74–85. [Google Scholar] [CrossRef]
- Torchilin, V.P. Liposomes as delivery agents for medical imaging. Mol. Med. Today 1996, 2, 242–249. [Google Scholar] [CrossRef]
- Arranja, A.G.; Pathak, V.; Lammers, T.; Shi, Y. Tumor-targeted nanomedicines for cancer theranostics. Pharmacol. Res. 2017, 115, 87–95. [Google Scholar] [CrossRef] [Green Version]
- Akhter, S.; Ahmad, I.; Ahmad, M.Z.; Ramazani, F.; Singh, A.; Rahman, Z.; Ahmad, F.J.; Storm, G.; Kok, R.J. Nanomedicines as cancer therapeutics: Current status. Curr. Cancer Drug Targets 2013, 13, 362–378. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Pérez-Herrero, E.; Fernández-Medarde, A. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy. Eur. J. Pharm. Biopharm. 2015, 93, 52–79. [Google Scholar] [CrossRef] [Green Version]
- Jain, R. Delivery of molecular medicine to solid tumors: Lessons from in vivo imaging of gene expression and function. J. Control. Release 2001, 74, 7–25. [Google Scholar] [CrossRef]
- Gao, Z.; Zhang, L.; Sun, Y. Nanotechnology applied to overcome tumor drug resistance. J. Control. Release 2012, 162, 45–55. [Google Scholar] [CrossRef]
- Liu, Y.; Lu, W. Recent advances in brain tumor-targeted nano-drug delivery systems. Expert Opin. Drug Deliv. 2012, 9, 671–686. [Google Scholar] [CrossRef]
- Matsumura, Y.; Maeda, H. A new concept for macromolecular therapeutics in cancer chemotherapy: Mechanism of tumoritropic accumulation of proteins and the anti-tumor agent smancs. Cancer Res. 1986, 46 Pt 1, 6387–6392. [Google Scholar] [PubMed]
- Maeda, H.; Wu, J.; Sawa, T.; Matsumura, Y.; Hori, K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: A review. J. Control. Release 2000, 65, 271–284. [Google Scholar] [CrossRef] [PubMed]
- Bertrand, N.; Leroux, J.-C. The journey of a drug-carrier in the body: An anatomo-physiological perspective. J. Control. Release 2012, 161, 152–163. [Google Scholar] [CrossRef] [PubMed]
- Alexis, F.; Pridgen, E.; Molnar, L.K.; Farokhzad, O.C. Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol. Pharm. 2008, 5, 505–515. [Google Scholar] [CrossRef] [Green Version]
- Radomski, A.; Jurasz, P.; Alonso-Escolano, D.; Drews, M.; Morandi, M.; Malinski, T.; Radomski, M.W. Nanoparticle-induced platelet aggregation and vascular thrombosis. Br. J. Pharmacol. 2005, 146, 882–893. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Albanese, A.; Tang, P.S.; Chan, W.C. The effect of nanoparticle size, shape, and surface chemistry on biological systems. Annu. Rev. Biomed. Eng. 2012, 14, 1–16. [Google Scholar] [CrossRef] [Green Version]
- Letchford, K.; Burt, H.M. Copolymer micelles and nanospheres with different in vitro stability demonstrate similar paclitaxel pharmacokinetics. Mol. Pharm. 2012, 9, 248–260. [Google Scholar] [CrossRef]
- Rijcken, C.J.F. Tuneable & Degradable Polymeric Micelles for Drug Delivery: From Synthesis to Feasibility In Vivo; Utrecht University: Utrecht, The Netherlands, 2007. [Google Scholar]
- Talelli, M.; Barz, M.; Rijcken, C.J.; Kiessling, F.; Hennink, W.E.; Lammers, T. Core-crosslinked polymeric micelles: Principles, preparation, biomedical applications and clinical translation. Nano Today 2015, 10, 93–117. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Wen, P.; Ke, W.; Dirisala, A.; Toh, K.; Tanaka, M.; Li, J. Stealth and pseudo-stealth nanocarriers. Adv. Drug Deliv. Rev. 2023, 198, 114895. [Google Scholar] [CrossRef]
- Shi, D.; Beasock, D.; Fessler, A.; Szebeni, J.; Ljubimova, J.Y.; Afonin, K.A.; Dobrovolskaia, M.A. To PEGylate or not to PEGylate: Immunological properties of nanomedicine’s most popular component, polyethylene glycol and its alternatives. Adv. Drug Deliv. Rev. 2022, 180, 114079. [Google Scholar] [CrossRef] [PubMed]
- d’Avanzo, N.; Celia, C.; Barone, A.; Carafa, M.; Di Marzio, L.; Santos, H.A.; Fresta, M. Immunogenicity of polyethylene glycol based nanomedicines: Mechanisms, clinical implications and systematic approach. Adv. Ther. 2020, 3, 1900170. [Google Scholar] [CrossRef]
- Emam, S.E.; Elsadek, N.E.; Lila, A.S.A.; Takata, H.; Kawaguchi, Y.; Shimizu, T.; Ando, H.; Ishima, Y.; Ishida, T. Anti-PEG IgM production and accelerated blood clearance phenomenon after the administration of PEGylated exosomes in mice. J. Control. Release 2021, 334, 327–334. [Google Scholar] [CrossRef] [PubMed]
- Gao, X.; Yan, X.; Wang, R.; Li, C.; Qiu, Q.; Liu, M.; Tang, X.; Yan, N.; Li, J.; Song, Y. Discovery in polyethylene glycol immunogenicity: The characteristic of intergenerational inheritance of anti-polyethylene glycol IgG. Eur. J. Pharm. Biopharm. 2022, 172, 89–100. [Google Scholar] [CrossRef]
- Okada, N.; Taro, S.; Ando, H.; Nakamura, S.; Goda, M.; Abe, M.; Kitahara, T.; Ishida, T.; Ishizawa, K. Clinical Impact of Antipolyethylene Glycol (PEG) Antibody in Hematological Patients Administered PEGylated-Granulocyte Colony-Stimulating Factor. Clin. Pharmacol. Drug Dev. 2023. [Google Scholar] [CrossRef]
- Mima, Y.; Lila, A.S.A.; Shimizu, T.; Ukawa, M.; Ando, H.; Kurata, Y.; Ishida, T. Ganglioside inserted into PEGylated liposome attenuates anti-PEG immunity. J. Control. Release 2017, 250, 20–26. [Google Scholar] [CrossRef]
- Belfiore, L.; Saunders, D.N.; Ranson, M.; Thurecht, K.J.; Storm, G.; Vine, K.L. Towards clinical translation of ligand-functionalized liposomes in targeted cancer therapy: Challenges and opportunities. J. Control. Release 2018, 277, 1–13. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Mukwaya, G.; Forssen, E.A.; Schmidt, P.; Ross, M. DaunoXome®(Liposomal Daunorubicin) for first-line treatment of advanced, HIV-related Kaposi’s Sarcoma. Long Circ. Liposomes Old Drugs New Ther. 1998, 147–163. [Google Scholar] [CrossRef]
- Gavas, S.; Quazi, S.; Karpiński, T.M. Nanoparticles for cancer therapy: Current progress and challenges. Nanoscale Res. Lett. 2021, 16, 173. [Google Scholar] [CrossRef] [PubMed]
- Fiandra, L.; Mazzucchelli, S.; De Palma, C.; Colombo, M.; Allevi, R.; Sommaruga, S.; Clementi, E.; Bellini, M.; Prosperi, D.; Corsi, F. Assessing the in vivo targeting efficiency of multifunctional nanoconstructs bearing antibody-derived ligands. ACS Nano 2013, 7, 6092–6102. [Google Scholar] [CrossRef]
- Park, D.H.; Cho, J.; Kwon, O.J.; Yun, C.O.; Choy, J.H. Biodegradable inorganic nanovector: Passive versus active tumor targeting in siRNA transportation. Angew. Chem. Int. Ed. 2016, 55, 4582–4586. [Google Scholar] [CrossRef]
- Jin, Z.; Lv, Y.; Cao, H.; Yao, J.; Zhou, J.; He, W.; Yin, L. Core-shell nanocarriers with high paclitaxel loading for passive and active targeting. Sci. Rep. 2016, 6, 27559. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Xiao, Q.; Zoulikha, M.; Qiu, M.; Teng, C.; Lin, C.; Li, X.; Sallam, M.A.; Xu, Q.; He, W. The effects of protein corona on in vivo fate of nanocarriers. Adv. Drug Deliv. Rev. 2022, 186, 114356. [Google Scholar] [CrossRef] [PubMed]
- Wang, X.; Zhang, W. The Janus of Protein Corona on nanoparticles for tumor targeting, immunotherapy and diagnosis. J. Control. Release 2022, 345, 832–850. [Google Scholar] [CrossRef]
- Li, J.; Kataoka, K. Chemo-physical strategies to advance the in vivo functionality of targeted nanomedicine: The next generation. J. Am. Chem. Soc. 2020, 143, 538–559. [Google Scholar] [CrossRef] [PubMed]
- Bürgi, J.; Abrami, L.; Castanon, I.; Abriata, L.A.; Kunz, B.; Yan, S.E.; Lera, M.; Unger, S.; Superti-Furga, A.; Dal Peraro, M. Ligand binding to the collagen VI receptor triggers a talin-to-RhoA switch that regulates receptor endocytosis. Dev. Cell 2020, 53, 418–430.e4. [Google Scholar] [CrossRef]
- Chen, P.; Yang, W.; Hong, T.; Miyazaki, T.; Dirisala, A.; Kataoka, K.; Cabral, H. Nanocarriers escaping from hyperacidified endo/lysosomes in cancer cells allow tumor-targeted intracellular delivery of antibodies to therapeutically inhibit c-MYC. Biomaterials 2022, 288, 121748. [Google Scholar] [CrossRef]
- Mura, S.; Nicolas, J.; Couvreur, P. Stimuli-responsive nanocarriers for drug delivery. Nat. Mater. 2013, 12, 991–1003. [Google Scholar] [CrossRef]
- Lu, Y.; Aimetti, A.A.; Langer, R.; Gu, Z. Bioresponsive materials. Nat. Rev. Mater. 2016, 2, 1–17. [Google Scholar] [CrossRef]
- Li, J.; Dirisala, A.; Ge, Z.; Wang, Y.; Yin, W.; Ke, W.; Toh, K.; Xie, J.; Matsumoto, Y.; Anraku, Y. Therapeutic Vesicular Nanoreactors with Tumor-Specific Activation and Self-Destruction for Synergistic Tumor Ablation. Angew. Chem. Int. Ed. 2017, 129, 14213–14218. [Google Scholar] [CrossRef]
- Shah, H.; Madni, A.; Filipczak, N.; Jan, N.; Khan, M.M.; Khan, S.; Basit, A.; Shafiq, A.; Rai, N.; Yalamarty, S.S.K.; et al. Cisplatin-loaded thermoresponsive liposomes for enhanced anti-cancer efficacy. J. Drug Deliv. Sci. Technol. 2023, 84, 104509. [Google Scholar] [CrossRef]
- Afzalipour, R.; Khoei, S.; Khoee, S.; Shirvalilou, S.; Raoufi, N.J.; Motevalian, M.; Karimi, M.Y. Thermosensitive magnetic nanoparticles exposed to alternating magnetic field and heat-mediated chemotherapy for an effective dual therapy in rat glioma model. Nanomed. Nanotechnol. Biol. Med. 2021, 31, 102319. [Google Scholar] [CrossRef]
- Swetha, K.L.; Paul, M.; Maravajjala, K.S.; Kumbham, S.; Biswas, S.; Roy, A. Overcoming drug resistance with a docetaxel and disulfiram loaded pH-sensitive nanoparticle. J. Control. Release 2023, 356, 93–114. [Google Scholar] [CrossRef] [PubMed]
- Di Francesco, M.; Celia, C.; Primavera, R.; D’Avanzo, N.; Locatelli, M.; Fresta, M.; Cilurzo, F.; Ventura, C.A.; Paolino, D.; Di Marzio, L. Physicochemical characterization of pH-responsive and fusogenic self-assembled non-phospholipid vesicles for a potential multiple targeting therapy. Int. J. Pharm. 2017, 528, 18–32. [Google Scholar] [CrossRef] [PubMed]
- Marianecci, C.; Di Marzio, L.; Del Favero, E.; Cantù, L.; Brocca, P.; Rondelli, V.; Rinaldi, F.; Dini, L.; Serra, A.; Decuzzi, P. Niosomes as drug nanovectors: Multiscale pH-dependent structural response. Langmuir 2016, 32, 1241–1249. [Google Scholar] [CrossRef]
- Li, J.; Ke, W.; Wang, L.; Huang, M.; Yin, W.; Zhang, P.; Chen, Q.; Ge, Z. Self-sufficing H2O2-responsive nanocarriers through tumor-specific H2O2 production for synergistic oxidation-chemotherapy. J. Control. Release 2016, 225, 64–74. [Google Scholar] [CrossRef] [PubMed]
- Li, J.; Ge, Z.; Toh, K.; Liu, X.; Dirisala, A.; Ke, W.; Wen, P.; Zhou, H.; Wang, Z.; Xiao, S. Enzymatically Transformable Polymersome-Based Nanotherapeutics to Eliminate Minimal Relapsable Cancer. Adv. Mater. 2021, 33, 2105254. [Google Scholar] [CrossRef]
- Barone, A.; d’Avanzo, N.; Cristiano, M.C.; Paolino, D.; Fresta, M. Macrophage-derived extracellular vesicles: A promising tool for personalized cancer therapy. Biomedicines 2022, 10, 1252. [Google Scholar] [CrossRef] [PubMed]
- Yan, Y.; Zhang, H.; Wei, S.; Xie, W.; Chen, Y.; Yang, H. Engineering extracellular vesicles derived from macrophages for tumor therapy: A review. Mater. Adv. 2023, 4, 1213–1225. [Google Scholar] [CrossRef]
- Wang, X.; Ding, H.; Li, Z.; Peng, Y.; Tan, H.; Wang, C.; Huang, G.; Li, W.; Ma, G.; Wei, W. Exploration and functionalization of M1-macrophage extracellular vesicles for effective accumulation in glioblastoma and strong synergistic therapeutic effects. Signal Transduct. Target. Ther. 2022, 7, 74. [Google Scholar] [CrossRef]
- Evers, M.J.; van de Wakker, S.I.; de Groot, E.M.; de Jong, O.G.; Gitz-François, J.J.; Seinen, C.S.; Sluijter, J.P.; Schiffelers, R.M.; Vader, P. Functional siRNA delivery by extracellular vesicle-liposome hybrid nanoparticles. Adv. Healthc. Mater. 2022, 11, 2101202. [Google Scholar] [CrossRef] [PubMed]
- Lin, Y.H.; Chen, C.-Y. Folate-targeted curcumin-encapsulated micellar nanosystem for chemotherapy and curcumin-mediated photodynamic therapy. Polymers 2020, 12, 2280. [Google Scholar] [CrossRef]
- Paolino, D.; Licciardi, M.; Celia, C.; Giammona, G.; Fresta, M.; Cavallaro, G. Folate-targeted supramolecular vesicular aggregates as a new frontier for effective anti-cancer treatment in in vivo model. Eur. J. Pharm. Biopharm. 2012, 82, 94–102. [Google Scholar] [CrossRef] [PubMed]
- Kumar, P.; Huo, P.; Liu, B. Formulation strategies for folate-targeted liposomes and their biomedical applications. Pharmaceutics 2019, 11, 381. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Liu, Y.; Dai, Z.; Wang, J.; Tu, Y.; Zhu, L. Folate-targeted pH-sensitive bortezomib conjugates for cancer treatment. Chem. Commun. 2019, 55, 4254–4257. [Google Scholar] [CrossRef]
- Celia, C.; Cristiano, M.C.; Froiio, F.; Di Francesco, M.; d’Avanzo, N.; Di Marzio, L.; Fresta, M. Nanoliposomes as multidrug carrier of gemcitabine/paclitaxel for the effective treatment of metastatic breast cancer disease: A comparison with Gemzar and Taxol. Adv. Ther. 2021, 4, 2000121. [Google Scholar] [CrossRef]
- Chen, Y.; Huang, Y.; Li, Q.; Luo, Z.; Zhang, Z.; Huang, H.; Sun, J.; Zhang, L.; Sun, R.; Bain, D.J. Targeting Xkr8 via nanoparticle-mediated in situ co-delivery of siRNA and chemotherapy drugs for cancer immunochemotherapy. Nat. Nanotechnol. 2023, 18, 193–204. [Google Scholar] [CrossRef]
- Li, W.; Chen, L.; Gu, Z.; Chen, Z.; Li, H.; Cheng, Z.; Li, H.; Zou, L. Co-delivery of microRNA-150 and quercetin by lipid nanoparticles (LNPs) for the targeted treatment of age-related macular degeneration (AMD). J. Control. Release 2023, 355, 358–370. [Google Scholar] [CrossRef]
- Ngamcherdtrakul, W.; Bejan, D.S.; Cruz-Muñoz, W.; Reda, M.; Zaidan, H.Y.; Siriwon, N.; Marshall, S.; Wang, R.; Nelson, M.A.; Rehwaldt, J.P. Targeted Nanoparticle for Co-delivery of HER2 siRNA and a Taxane to Mirror the Standard Treatment of HER2+ Breast Cancer: Efficacy in Breast Tumor and Brain Metastasis. Small 2022, 18, 2107550. [Google Scholar] [CrossRef]
- Zhang, M.; Hagan IV, C.T.; Foley, H.; Tian, X.; Yang, F.; Au, K.M.; Mi, Y.; Medik, Y.; Roche, K.; Wagner, K. Co-delivery of etoposide and cisplatin in dual-drug loaded nanoparticles synergistically improves chemoradiotherapy in non-small cell lung cancer models. Acta Biomater. 2021, 124, 327–335. [Google Scholar] [CrossRef]
- Li, J.; Li, Y.; Wang, Y.; Ke, W.; Chen, W.; Wang, W.; Ge, Z. Polymer prodrug-based nanoreactors activated by tumor acidity for orchestrated oxidation/chemotherapy. Nano Lett. 2017, 17, 6983–6990. [Google Scholar] [CrossRef]
- Han, Y.; Wen, P.; Li, J.; Kataoka, K. Targeted nanomedicine in cisplatin-based cancer therapeutics. J. Control. Release 2022, 345, 709–720. [Google Scholar] [CrossRef] [PubMed]
- White, S.C.; Lorigan, P.; Margison, G.P.; Margison, J.M.; Martin, F.; Thatcher, N.; Anderson, H.; Ranson, M. Phase II study of SPI-77 (sterically stabilised liposomal cisplatin) in advanced non-small-cell lung cancer. Br. J. Cancer 2006, 95, 822–828. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Nishiyama, N.; Okazaki, S.; Cabral, H.; Miyamoto, M.; Kato, Y.; Sugiyama, Y.; Nishio, K.; Matsumura, Y.; Kataoka, K. Novel cisplatin-incorporated polymeric micelles can eradicate solid tumors in mice. Cancer Res. 2003, 63, 8977–8983. [Google Scholar]
- Doi, T.; Hamaguchi, T.; Shitara, K.; Iwasa, S.; Shimada, Y.; Harada, M.; Naito, K.; Hayashi, N.; Masada, A.; Ohtsu, A. NC-6004 Phase I study in combination with gemcitabine for advanced solid tumors and population PK/PD analysis. Cancer Chemother. Pharmacol. 2017, 79, 569–578. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Subbiah, V.; Grilley-Olson, J.E.; Combest, A.J.; Sharma, N.; Tran, R.H.; Bobe, I.; Osada, A.; Takahashi, K.; Balkissoon, J.; Camp, A. Phase Ib/II Trial of NC-6004 (Nanoparticle Cisplatin) Plus Gemcitabine in Patients with Advanced Solid TumorsNC-6004/Gemcitabine in Patients with Advanced Solid Tumors. Clin. Cancer Res. 2018, 24, 43–51. [Google Scholar] [CrossRef] [Green Version]
- Volovat, S.R.; Ciuleanu, T.-E.; Koralewski, P.; Olson, J.E.G.; Croitoru, A.; Koynov, K.; Stabile, S.; Cerea, G.; Osada, A.; Bobe, I. A multicenter, single-arm, basket design, phase II study of NC-6004 plus gemcitabine in patients with advanced unresectable lung, biliary tract, or bladder cancer. Oncotarget 2020, 11, 3105. [Google Scholar] [CrossRef]
- Osada, A.; Mangel, L.; Fijuth, J.; Żurawski, B.; Ursulovic, T.; Nikolin, B.; Djan, I.; Olson, J.G. Phase IIa/IIb clinical trial of NC-6004 (Nanoparticle Cisplatin) plus Pembrolizumab in patients with head and neck cancer (HNSCC) who have failed platinum or a platinum-containing regimen. Eur. J. Cancer 2020, 138, S35. [Google Scholar] [CrossRef]
- Pourhassan, H.; Clergeaud, G.; Hansen, A.E.; Østrem, R.G.; Fliedner, F.P.; Melander, F.; Nielsen, O.L.; O’Sullivan, C.K.; Kjær, A.; Andresen, T.L. Revisiting the use of sPLA2-sensitive liposomes in cancer therapy. J. Control. Release 2017, 261, 163–173. [Google Scholar] [CrossRef] [PubMed]
- Oerlemans, C.; Bult, W.; Bos, M.; Storm, G.; Nijsen, J.F.W.; Hennink, W.E. Polymeric micelles in anti-cancer therapy: Targeting, imaging and triggered release. Pharm. Res. 2010, 27, 2569–2589. [Google Scholar] [CrossRef] [Green Version]
- Mangues, R.; Vázquez, E.; Villaverde, A. Targeting in cancer therapies. Med. Sci. 2016, 4, 6. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Zhao, X.; Guo, B.; Wu, H.; Liang, Y.; Ma, P.X. Injectable antibacterial conductive nanocomposite cryogels with rapid shape recovery for noncompressible hemorrhage and wound healing. Nat. Commun. 2018, 9, 2784. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Zhao, T.; Huang, G.; Li, Y.; Yang, S.; Ramezani, S.; Lin, Z.; Wang, Y.; Ma, X.; Zeng, Z.; Luo, M.; et al. A Transistor-like pH Nanoprobe for Tumour Detection and Image-guided Surgery. Nat. Biomed. Eng. 2016, 1, 6. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Wang, P.; Fan, Y.; Lu, L.; Liu, L.; Fan, L.; Zhao, M.; Xie, Y.; Xu, C.; Zhang, F. NIR-II nanoprobes in-vivo assembly to improve image-guided surgery for metastatic ovarian cancer. Nat. Commun. 2018, 9, 2898. [Google Scholar] [CrossRef] [Green Version]
- Kircher, M.F.; Mahmood, U.; King, R.S.; Weissleder, R.; Josephson, L. A multimodal nanoparticle for preoperative magnetic resonance imaging and intraoperative optical brain tumor delineation. Cancer Res. 2003, 63, 8122–8125. [Google Scholar]
- Hou, Y.; Sun, Z.; Rao, W.; Liu, J. Nanoparticle-mediated cryosurgery for tumor therapy. Nanomedicine 2018, 14, 493–506. [Google Scholar] [CrossRef] [PubMed]
- Deng, Z.S.; Liu, J. Numerical simulation of selective freezing of target biological tissues following injection of solutions with specific thermal properties. Cryobiology 2005, 50, 183–192. [Google Scholar] [CrossRef]
- Sivak, L.; Subr, V.; Tomala, J.; Rihova, B.; Strohalm, J.; Etrych, T.; Kovar, M. Overcoming multidrug resistance via simultaneous delivery of cytostatic drug and P-glycoprotein inhibitor to cancer cells by HPMA copolymer conjugate. Biomaterials 2017, 115, 65–80. [Google Scholar] [CrossRef] [PubMed]
- Zhang, L.; Zhang, B.; Liang, R.; Ran, H.; Zhu, D.; Ren, J.; Liu, L.; Ma, A.; Cai, L. A Dual-Biomineralized Yeast Micro-/Nanorobot with Self-Driving Penetration for Gastritis Therapy and Motility Recovery. ACS Nano 2023, 17, 6410–6422. [Google Scholar] [CrossRef]
- Lin, T.; Zhao, P.; Jiang, Y.; Tang, Y.; Jin, H.; Pan, Z.; He, H.; Yang, V.C.; Huang, Y. Blood-Brain-Barrier-Penetrating Albumin Nanoparticles for Biomimetic Drug Delivery via Albumin-Binding Protein Pathways for Antiglioma Therapy. ACS Nano 2016, 10, 9999–10012. [Google Scholar] [CrossRef] [PubMed]
- Fan, W.; Bu, W.; Zhang, Z.; Shen, B.; Zhang, H.; He, Q.; Ni, D.; Cui, Z.; Zhao, K.; Bu, J.; et al. X-ray Radiation-Controlled NO-Release for On-Demand Depth-Independent Hypoxic Radiosensitization. Angew. Chem. Int. Ed. 2015, 54, 14026–14030. [Google Scholar] [CrossRef] [PubMed]
- Fan, W.; Yung, B.; Huang, P.; Chen, X. Nanotechnology for Multimodal Synergistic Cancer Therapy. Chem. Rev. 2017, 117, 13566–13638. [Google Scholar] [CrossRef]
- Song, G.; Ji, C.; Liang, C.; Song, X.; Yi, X.; Dong, Z.; Yang, K.; Liu, Z. TaOx decorated perfluorocarbon nanodroplets as oxygen reservoirs to overcome tumor hypoxia and enhance cancer radiotherapy. Biomaterials 2017, 112, 257–263. [Google Scholar] [CrossRef]
- Swanner, J.; Mims, J.; Carroll, D.L.; Akman, S.A.; Furdui, C.M.; Torti, S.V.; Singh, R.N. Differential cytotoxic and radiosensitizing effects of silver nanoparticles on triple-negative breast cancer and non-triple-negative breast cells. Int. J. Nanomed. 2015, 10, 3937–3953. [Google Scholar]
- Zheng, Q.; Yang, H.; Wei, J.; Tong, J.L.; Shu, Y.Q. The role and mechanisms of nanoparticles to enhance radiosensitivity in hepatocellular cell. Biomed. Pharmacother. 2013, 67, 569–575. [Google Scholar] [CrossRef]
- Yuan, H.; Chong, H.; Wang, B.; Zhu, C.; Liu, L.; Yang, Q.; Lv, F.; Wang, S. Chemical molecule-induced light-activated system for anti-cancer and antifungal activities. J. Am. Chem. Soc. 2012, 134, 13184–13187. [Google Scholar] [CrossRef]
- Ji, B.; Wei, M.; Yang, B. Recent advances in nanomedicines for photodynamic therapy (PDT)-driven cancer immunotherapy. Theranostics 2022, 12, 434–458. [Google Scholar] [CrossRef]
- Yang, Y.; Zhu, W.; Feng, L.; Chao, Y.; Yi, X.; Dong, Z.; Yang, K.; Tan, W.; Liu, Z.; Chen, M. G-Quadruplex-Based Nanoscale Coordination Polymers to Modulate Tumor Hypoxia and Achieve Nuclear-Targeted Drug Delivery for Enhanced Photodynamic Therapy. Nano Lett. 2018, 18, 6867–6875. [Google Scholar] [CrossRef]
- Tian, J.; Xiao, C.; Huang, B.; Wang, C.; Zhang, W. Janus macromolecular brushes for synergistic cascade-amplified photodynamic therapy and enhanced chemotherapy. Acta Biomater. 2020, 101, 495–506. [Google Scholar] [CrossRef] [PubMed]
- Wang, M.; Zhai, Y.; Ye, H.; Lv, Q.; Sun, B.; Luo, C.; Jiang, Q.; Zhang, H.; Xu, Y.; Jing, Y.; et al. High Co-loading Capacity and Stimuli-Responsive Release Based on Cascade Reaction of Self-Destructive Polymer for Improved Chemo-Photodynamic Therapy. ACS Nano 2019, 13, 7010–7023. [Google Scholar] [CrossRef] [PubMed]
- Liang, R.; Liu, L.; He, H.; Chen, Z.; Han, Z.; Luo, Z.; Wu, Z.; Zheng, M.; Ma, Y.; Cai, L. Oxygen-boosted immunogenic photodynamic therapy with gold nanocages@manganese dioxide to inhibit tumor growth and metastases. Biomaterials 2018, 177, 149–160. [Google Scholar] [CrossRef] [PubMed]
- Xu, J.; Xu, L.; Wang, C.; Yang, R.; Zhuang, Q.; Han, X.; Dong, Z.; Zhu, W.; Peng, R.; Liu, Z. Near-Infrared-Triggered Photodynamic Therapy with Multitasking Upconversion Nanoparticles in Combination with Checkpoint Blockade for Immunotherapy of Colorectal Cancer. ACS Nano 2017, 11, 4463–4474. [Google Scholar] [CrossRef] [PubMed]
- Hussein, E.A.; Zagho, M.M.; Nasrallah, G.K.; Elzatahry, A.A. Recent advances in functional nanostructures as cancer photothermal therapy. Int. J. Nanomed. 2018, 13, 2897–2906. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Wei, G.; Wang, Y.; Yang, G.; Wang, Y.; Ju, R. Recent progress in nanomedicine for enhanced cancer chemotherapy. Theranostics 2021, 11, 6370–6392. [Google Scholar] [CrossRef]
- Li, R.; Zhang, L.; Shi, L.; Wang, P. MXene Ti(3)C(2): An Effective 2D Light-to-Heat Conversion Material. ACS Nano 2017, 11, 3752–3759. [Google Scholar] [CrossRef] [Green Version]
- Su, S.; Ding, Y.; Li, Y.; Wu, Y.; Nie, G. Integration of photothermal therapy and synergistic chemotherapy by a porphyrin self-assembled micelle confers chemosensitivity in triple-negative breast cancer. Biomaterials 2016, 80, 169–178. [Google Scholar] [CrossRef]
- Ali, M.R.; Wu, Y.; Han, T.; Zang, X.; Xiao, H.; Tang, Y.; Wu, R.; Fernández, F.M.; El-Sayed, M.A. Simultaneous Time-Dependent Surface-Enhanced Raman Spectroscopy, Metabolomics, and Proteomics Reveal Cancer Cell Death Mechanisms Associated with Gold Nanorod Photothermal Therapy. J. Am. Chem. Soc. 2016, 138, 15434–15442. [Google Scholar] [CrossRef]
- Vaughan, H.J.; Green, J.J.; Tzeng, S.Y. Cancer-Targeting Nanoparticles for Combinatorial Nucleic Acid Delivery. Adv. Mater. 2020, 32, e1901081. [Google Scholar] [CrossRef] [PubMed]
- Dizaj, S.M.; Jafari, S.; Khosroushahi, A.Y. A sight on the current nanoparticle-based gene delivery vectors. Nanoscale Res. Lett. 2014, 9, 252. [Google Scholar] [CrossRef] [Green Version]
- Islam, M.A.; Xu, Y.; Tao, W.; Ubellacker, J.M.; Lim, M.; Aum, D.; Lee, G.Y.; Zhou, K.; Zope, H.; Yu, M.; et al. Restoration of tumour-growth suppression in vivo via systemic nanoparticle-mediated delivery of PTEN mRNA. Nat. Biomed. Eng. 2018, 2, 850–864. [Google Scholar] [CrossRef] [PubMed]
- Wu, Y.; Wang, W.; Chen, Y.; Huang, K.; Shuai, X.; Chen, Q.; Li, X.; Lian, G. The investigation of polymer-siRNA nanoparticle for gene therapy of gastric cancer in vitro. Int. J. Nanomed. 2010, 5, 129–136. [Google Scholar] [CrossRef] [Green Version]
- Ren, K.; Liu, Y.; Wu, J.; Zhang, Y.; Zhu, J.; Yang, M.; Ju, H. A DNA dual lock-and-key strategy for cell-subtype-specific siRNA delivery. Nat. Commun. 2016, 7, 13580. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Wang, J.; Sui, M.; Fan, W. Nanoparticles for tumor targeted therapies and their pharmacokinetics. Curr. Drug Metab. 2010, 11, 129–141. [Google Scholar] [CrossRef] [Green Version]
- Lee, N.; Choi, S.H.; Hyeon, T. Nano-sized CT contrast agents. Adv. Mater. 2013, 25, 2641–2660. [Google Scholar] [CrossRef] [PubMed]
- Mojarrad, P.; Zamani, S.; Seyedhamzeh, M.; Omoomi, F.D.; Karimpourfard, N.; Hadadian, S.; Ebrahimi, S.E.S.; Hamedani, M.P.; Farzaneh, J.; Ardestani, M.S. Novel radiopharmaceutical (Technetium-99m)-(DOTA-NHS-ester)-Methionine as a SPECT-CT tumor imaging agent. Eur. J. Pharm. Sci. 2020, 141, 105112. [Google Scholar] [CrossRef]
- Kim, S.M.; Faix, P.H.; Schnitzer, J.E. Overcoming key biological barriers to cancer drug delivery and efficacy. J. Control. Release 2017, 267, 15–30. [Google Scholar] [CrossRef]
- Urbanczyk, M.; Zbinden, A.; Schenke-Layland, K. Organ-specific endothelial cell heterogenicity and its impact on regenerative medicine and biomedical engineering applications. Adv. Drug Deliv. Rev. 2022, 186, 114323. [Google Scholar] [CrossRef] [PubMed]
- Nagy, J.A.; Chang, S.-H.; Shih, S.-C.; Dvorak, A.M.; Dvorak, H.F. Heterogeneity of the tumor vasculature. Semin. Thromb. Hemost. 2010, 36, 321–331. [Google Scholar] [CrossRef] [PubMed] [Green Version]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Xu, M.; Han, X.; Xiong, H.; Gao, Y.; Xu, B.; Zhu, G.; Li, J. Cancer Nanomedicine: Emerging Strategies and Therapeutic Potentials. Molecules 2023, 28, 5145. https://doi.org/10.3390/molecules28135145
Xu M, Han X, Xiong H, Gao Y, Xu B, Zhu G, Li J. Cancer Nanomedicine: Emerging Strategies and Therapeutic Potentials. Molecules. 2023; 28(13):5145. https://doi.org/10.3390/molecules28135145
Chicago/Turabian StyleXu, Manman, Xinpu Han, Hongtai Xiong, Yijie Gao, Bowen Xu, Guanghui Zhu, and Jie Li. 2023. "Cancer Nanomedicine: Emerging Strategies and Therapeutic Potentials" Molecules 28, no. 13: 5145. https://doi.org/10.3390/molecules28135145